DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Any EGFR TKI - 100004


DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Any EGFR TKI

imedex has 1311 videos Subscribe Here

Description: The Great Debates and Updates in Thoracic Malignancies 2015 conference focuses on controversial areas in the management of patients with lung and other thoracic cancers, with nationally-recognized thought leaders taking opposing sides on topics of interest to physicians and their patients.

Using didactic presentations in conjunction with lively and instructive debates, this exciting and comprehensive conference gives practicing clinicians a thorough analysis of all currently available and emerging data. Recognized thought leaders discuss and debate a variety of controversial topics, including management strategies for common mutations in lung cancer and utilization of molecular biomarker profile of the tumors to guide therapeutic decisions.

In this presentation, Dr. Edward B. Garon argues in favor of using any EGFR TKI for the treatment ofexon 19 deletion, EGFR-mutant Non-Small Cell Lung Cancer (NSCLC).

A continuing education program is offered as a supplement to this webcast at the following location:

© 2015 Imedex, LLC.
Shared By : imedex
Posted on : 11/13/15
Added : 3 years ago
Category :